贝伐单抗，也是没有用的情况下鳞状细胞癌，因为它会导致出血，从这种类型的肺癌。
Bevacizumab is also not used in cases of squamous cell cancer, because it leads to bleeding from this type of lung cancer.
排除鳞状细胞肺癌的患者和那些治疗前有咯血的患者后，贝伐单抗治疗导致的致命率就会下降到1.9%。
By excluding patients with squamous-cell lung cancer and those with hemoptysis prior to treatment, the rate was brought down to 1.9%.
排除鳞状细胞肺癌的患者和那些治疗前有咯血的患者后，贝伐单抗治疗导致的致命率就会下降到1.9%。
By excluding patients with squamous-cell lung cancer and those with hemoptysis prior to treatment, the rate was brought down to 1.9%.
应用推荐